Sebastian Völz1, Jonas Spaak2, Johan Elf3, Christina Jägrén4, Christer Lundin5, Anna Stenborg6, Jonas Andersson7, Bengt Rundqvist1, Thomas Kahan2, Bert Andersson1. 1. Department of Cardiology, Sahlgrenska Academy at Gothenburg University, Gothenburg. 2. Division of Cardiovascular Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm. 3. Department of Vascular Diseases, Skåne University Hospital, Malmö. 4. Department of Cardiology, South General Hospital, Stockholm. 5. Department of Cardiology, Örebro University Hospital, Örebro. 6. Department of Internal Medicine, Uppsala University Hospital, Uppsala, Sweden. 7. Department of Cardiology, Umeå University Hospital, Umeå.
Abstract
BACKGROUND: Renal denervation (RDN) is a catheter-based intervention to treat patients with resistant hypertension. The biological effects of RDN are not fully understood, and randomized controlled trials have generated conflicting evidence. This report presents data from the Swedish Registry for Renal Denervation, an investigator-driven nationwide registry. PURPOSE: To assess the safety and efficacy of RDN on patients with resistant hypertension in a real-world clinical setting. METHODS: This nationwide database contains patient characteristics, procedural details, and follow-up data on all RDN procedures performed in Sweden. Consecutive procedures between 2011 and 2015 were included. RESULTS: The data analysis consists of 252 patients (mean age 61 ± 10 years, 38% women; mean 4.5 ± 1.5 antihypertensive drugs). Office SBP and DBP and 24-h ambulatory blood pressure (BP) decreased 6 months after RDN (176 ± 23/97 ± 17 to 161 ± 26/91 ± 16 mmHg, both P < 0.001; and 155 ± 17/89 ± 14 to 147 ± 18/82 ± 12 mmHg, both P < 0.001). Significant office and ambulatory BP reductions persisted throughout the observation period of 36 months. Major procedure-related vascular complications occurred in four patients. Renal function and number of antihypertensive drugs were unchanged during follow-up. CONCLUSION: In this complete national cohort, RDN was associated with a sustained reduction in office and ambulatory BP in patients with resistant hypertension. The procedure proved to be feasible and associated with a low-complication rate, including long-term adverse events.
BACKGROUND: Renal denervation (RDN) is a catheter-based intervention to treat patients with resistant hypertension. The biological effects of RDN are not fully understood, and randomized controlled trials have generated conflicting evidence. This report presents data from the Swedish Registry for Renal Denervation, an investigator-driven nationwide registry. PURPOSE: To assess the safety and efficacy of RDN on patients with resistant hypertension in a real-world clinical setting. METHODS: This nationwide database contains patient characteristics, procedural details, and follow-up data on all RDN procedures performed in Sweden. Consecutive procedures between 2011 and 2015 were included. RESULTS: The data analysis consists of 252 patients (mean age 61 ± 10 years, 38% women; mean 4.5 ± 1.5 antihypertensive drugs). Office SBP and DBP and 24-h ambulatory blood pressure (BP) decreased 6 months after RDN (176 ± 23/97 ± 17 to 161 ± 26/91 ± 16 mmHg, both P < 0.001; and 155 ± 17/89 ± 14 to 147 ± 18/82 ± 12 mmHg, both P < 0.001). Significant office and ambulatory BP reductions persisted throughout the observation period of 36 months. Major procedure-related vascular complications occurred in four patients. Renal function and number of antihypertensive drugs were unchanged during follow-up. CONCLUSION: In this complete national cohort, RDN was associated with a sustained reduction in office and ambulatory BP in patients with resistant hypertension. The procedure proved to be feasible and associated with a low-complication rate, including long-term adverse events.
Authors: Melvin D Lobo; Andrew S P Sharp; Vikas Kapil; Justin Davies; Mark A de Belder; Trevor Cleveland; Clare Bent; Neil Chapman; Indranil Dasgupta; Terry Levy; Anthony Mathur; Matthew Matson; Manish Saxena; Francesco P Cappuccio Journal: Heart Date: 2019-07-10 Impact factor: 5.994
Authors: Andrew S P Sharp; Stefan Tunev; Markus Schlaich; David P Lee; Aloke V Finn; Julie Trudel; Douglas A Hettrick; Felix Mahfoud; David E Kandzari Journal: J Hypertens Date: 2022-07-18 Impact factor: 4.776
Authors: Alexander Reshetnik; Christopher Gohlisch; Christian Scheurig-Münkler; Maximilian De Bucourt; Walter Zidek; Markus Tölle; Markus van der Giet Journal: Sci Rep Date: 2018-10-19 Impact factor: 4.379
Authors: Marit D Solbu; Atena Miroslawska; Jon V Norvik; Bjørn O Eriksen; Terje K Steigen Journal: J Clin Hypertens (Greenwich) Date: 2021-02-16 Impact factor: 3.738